PNC-27 20mg — Vial Spec, Reconstitution Math & COA

Overview of PNC-27 20mg Research Vials

A 20mg vial of PNC-27 contains a highly concentrated, sterile lyophilized cake of the membrane-active peptide designed specifically for high-volume in vitro assays, high-throughput screening, and structural biophysics studies. Laboratory researchers routinely select the 20mg unit specification when executing multi-well cell culture panels, microfluidic chamber perfusion experiments, or structural NMR spectroscopy trials where standardized stock solutions must be maintained across broad treatment matrices.

PNC-27 is a synthetic peptide derived from the p53 sequence (residues 12–26) linked to a transmembrane-penetrating leader sequence (penetratin). As a specialized research compound, the 20mg format eliminates the inter-vial variation that can occur when aggregating multiple smaller vials (such as 2mg or 5mg formats) during large-scale experimental runs. For laboratories seeking to verify current catalog stock or bulk availability, visit our comprehensive research peptide inventory or inspect the dedicated PNC-27 product page for active stock configurations and lot scheduling.

Please note that while high-mass specifications like 20mg are frequently requested for high-throughput laboratory workflows, PX1 Research maintains flexible production schedules. If the exact 20mg standard vial size is currently listed as a custom build or non-standard SKU on our portal, researchers can coordinate custom fills through our wholesale accounts department or utilize multiple standard unit sizes to fulfill identical total target masses.

Molecular Role and Mechanism of Action in Preclinical Models

In preclinical literature, PNC-27 is categorized primarily as a membrane-active anticancer peptide. Unlike classical chemotherapeutic agents or gene therapy constructs that rely on intranuclear genomic signaling, PNC-27 targets cell membranes directly. Preclinical studies suggest that PNC-27 selectively binds to membrane-bound Human Double Minute-2 (HDM-2) protein complexes expressed on the surface of transformed tumor cells, while exhibiting negligible affinity for non-transformed somatic cell membranes.

In vitro data indicate that upon binding to membrane-bound HDM-2, PNC-27 undergoes a conformational shift that induces rapid transmembrane pore formation. This mechanism triggers direct cell lysis and rapid necrosis within minutes of contact. Remarkably, this process operates completely independent of the p53 pathway; even p53-null or p53-mutated cancer cell lines demonstrate susceptibility to PNC-27-mediated membrane dissolution in laboratory models.

Researchers evaluating structural cell biology routinely utilize PNC-27 to investigate the mechanics of peptide-lipid interactions, receptor-independent membrane destruction, and tumor-selective surface markers. High-density 20mg preparations allow investigators to perform continuous dose-response studies across diverse cell lines without introducing batch-to-batch reconstitution variables.

Reconstitution Math for 20mg Lyophilized Vials

Accurate reconstitution of a 20mg PNC-27 vial is essential for maintaining precise molarity and mass concentrations across cell culture treatments. Because 20mg represents a substantial mass of peptide, researchers must carefully select diluent volume based on desired working stock concentrations, solubility limits, and the viscosity tolerances of experimental delivery apparatuses.

When calculating concentration, the basic formula is Mass (mg) / Volume (mL) = Concentration (mg/mL). To determine the precise micro-liter volumes required for microplate dosing, researchers should utilize our interactive reconstitution calculator. Below are the primary reconstitution models for a 20mg vial using standard sterile laboratory diluents such as bacteriostatic water, sterile 0.9% saline, or cell-culture grade phosphate-buffered saline (PBS):

1.0 mL Diluent Addition: Adding exactly 1.0 mL of diluent yields a highly concentrated working stock of 20.0 mg/mL (20.0 µg/µL). This high-density stock is optimal for primary micro-aliquoting or high-dose microfluidic assays requiring minimal liquid volume displacement in culture wells.

2.0 mL Diluent Addition: Adding 2.0 mL of diluent yields a stock concentration of 10.0 mg/mL (10.0 µg/µL). This standardized 1:1 ratio simplifies volumetric calculations during automated liquid handler pipetting and multi-concentration serial dilutions.

3.0 mL Diluent Addition: Adding 3.0 mL of diluent produces a stock concentration of 6.67 mg/mL (6.67 µg/µL). This lower concentration is frequently utilized when larger working volumes are required to ensure uniform mixing across large culture flasks or high-surface-area petri dishes without exceeding localized osmolarity thresholds.

Aliquot Strategy, Handling, and Solubility Protocols

To preserve the structural integrity of PNC-27 post-reconstitution, laboratory personnel must implement a rigorous aliquot strategy. Lyophilized peptides subjected to repeated freeze-thaw cycles undergo mechanical stress that leads to peptide aggregation, peptide bond cleavage, and loss of biological activity. Following complete dissolution of the 20mg cake, the stock solution should be divided immediately into single-use micro-aliquots (e.g., 50 µL to 100 µL) inside polypropylene low-binding microcentrifuge tubes.

Dissolution of PNC-27 should be achieved using gentle swirl motion at ambient room temperature (20°C to 25°C). Violent vortexing or high-shear physical agitation must be strictly avoided, as surface tension changes can cause peptide denaturation and foam formation. If complete clarity is not achieved immediately upon diluent addition, allow the vial to stand quiescently on ice for 5 to 10 minutes to permit full hydration of the peptide matrix.

When preparing working stock solutions for long-term cell culture studies, researchers should verify solvent compatibility. While PNC-27 demonstrates high aqueous solubility in standard aqueous diluents, assays requiring neutral pH stability under serum-free media conditions should monitor for micro-precipitation. Detailed protocols for handling challenging peptide sequences can be reviewed in our research library.

Quality Control, Purity Verification, and Lot-Matched COA

PX1 Research enforces stringent analytical quality control protocols across all manufacturing operations. Every batch of PNC-27 undergoes comprehensive identity, purity, and safety verification prior to packaging. The primary analytical techniques employed include High-Performance Liquid Chromatography (HPLC) to verify chromatographic purity (guaranteed ≥98%) and Mass Spectrometry (MS) to confirm exact molecular weight matched to theoretical sequence values.

In addition to structural purity, PX1 Research evaluates total bacterial endotoxin levels using kinetic chromogenic LAL testing to ensure levels remain well below critical thresholds for sensitive cell culture assays (<0.01 EU/mg). Moisture content analysis (Karl Fischer titration) guarantees that residual water content does not degrade peptide stability during prolonged dry storage.

Every 20mg vial shipped is assigned a lot-specific identification code that links directly to its analytical documentation. Laboratory directors can review and download certified analytical records by visiting our centralized Certificate of Analysis database. This transparency ensures that experimental data collected using PX1 compounds remains reproducible and audit-ready.

Storage Protocols and Lyophilized Stability Metrics

Proper temperature control is vital to maintaining the chemical stability of PNC-27. In its un-reconstituted, lyophilized state, the 20mg vial should be stored in a commercial freezer maintained at -20°C for short-to-medium term storage (up to 12 months) or -80°C for long-term archival preservation (up to 24 months). Store vials protected from direct light exposure inside sealed desiccant containers to eliminate moisture accumulation.

Prior to opening and reconstituting a frozen vial, allow the container to equilibrate to room temperature for approximately 30 to 60 minutes. Opening a cold vial in a humid laboratory atmosphere causes ambient moisture to condense rapidly onto the lyophilized powder, promoting immediate chemical degradation via hydrolysis.

Once reconstituted into aqueous liquid solution, PNC-27 working stocks must be maintained at 2°C to 8°C if used within 24 to 48 hours. For extended usage windows up to 30–60 days, liquid aliquots must be frozen immediately at -20°C or -80°C. Never store reconstituted liquid peptides in auto-defrost (frost-free) freezers, as the thermal cycling loops inherent to these units accelerate peptide degradation.

Evaluating Format Options: 20mg vs. Alternate Vial Sizes

Determining whether a 20mg vial format or smaller incremental unit sizes (such as 2mg or 5mg) represent the optimal procurement path depends on specific laboratory workflow mechanics. High-mass 20mg vials offer distinct economic and operational efficiencies for laboratories executing continuous daily assays, automated liquid handler screens, or large-scale comparative toxicity panels.

However, for sporadic preliminary testing, single-assay exploratory trials, or pilot stability tests, smaller unit sizes may be preferable to minimize the total volume of liquid stock held in frozen storage. Procuring smaller formats ensures that material is consumed within a single experimental workflow, completely bypassing the risks associated with extended storage of reconstituted solutions.

When planning procurement, research teams should evaluate total required mass, target final assay concentration, and aliquot storage capacity. Standard unit sizes and custom lot sizes can be cross-referenced within our main catalog at /all-peptides or discussed directly with our technical support team.

Comparative Analysis: PNC-27 and Related Oncology Research Peptides

To contextualize PNC-27 within broader cell biology literature, researchers often compare its membrane-active mechanics with other targeted oncological or cell-penetrating research peptides. Understanding structural distinctions helps principal investigators select the appropriate compound class for specific in vitro endpoints.

For example, while PNC-27 operates via HDM-2 binding and membrane pore formation, peptides such as FOXO4-DRI target senescent cell viability through p53-FOXO4 interaction interference, initiating targeted apoptotic signaling pathways rather than mechanical pore-mediated necrosis. Similarly, research investigating tissue repair and cellular protection mechanisms often employs signaling peptides like BPC-157 5mg, which activate angiogenic and migratory pathways rather than membrane dissolution.

By comparing these distinct mechanisms—direct membrane pore formation versus intracellular signaling modulation—investigators can design comprehensive multi-peptide assay panels to evaluate tumor microenvironment responses across diverse stress paradigms.

Experimental Applications in In Vitro Transmembrane Studies

In published preclinical methodologies, PNC-27 is frequently utilized in fluorescence microscopy, flow cytometry, and electrophysiological membrane patch-clamp experiments. Researchers introduce fluorophore-tagged PNC-27 to observe real-time spatial localization to HDM-2 membrane clusters on target cancer cell lines versus normal somatic controls.

In electrophysiological setups, application of PNC-27 to isolated lipid bilayers or target cell membranes allows precise measurement of transmembrane conductance changes as pore formation occurs. The rapid kinetic onset of membrane permeability—often occurring within 10 to 15 minutes of exposure—makes PNC-27 an ideal positive control for membrane disruption studies.

All experimental designs using PNC-27 must strictly adhere to in vitro containment protocols. PX1 Research supplies PNC-27 exclusively for laboratory research use; it is strictly prohibited for clinical, human, or veterinary applications.